Shunsuke Kondo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2186372/publications.pdf

Version: 2024-02-01

104	2,338	257450	265206
papers	citations	24 h-index	42 g-index

108	108	108	4175
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. Japanese Journal of Clinical Oncology, 2022, 52, 716-724.	1.3	6
2	Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies. Cancer Chemotherapy and Pharmacology, 2021, 87, 53-64.	2.3	6
3	Model Informed Dosing Regimen and Phase I Results of the Antiâ€PDâ€1 Antibody Budigalimab (ABBVâ€181). Clinical and Translational Science, 2021, 14, 277-287.	3.1	5
4	Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. Journal of Gastroenterology, 2021, 56, 181-190.	5.1	20
5	Firstâ€inâ€human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. Cancer Science, 2021, 112, 1514-1523.	3.9	6
6	Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. Immunotherapy, 2021, 13, 371-385.	2.0	16
7	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFÎ² and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. Targeted Oncology, 2021, 16, 447-459.	3.6	16
8	Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study. Cancer Medicine, 2021, 10, 6579-6589.	2.8	4
9	First-In-Human Phase I Study of a Next-Generation, Oral, TGFÎ² Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clinical Cancer Research, 2021, 27, 6666-6676.	7.0	27
10	Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. Cancer Treatment and Research Communications, 2021, 28, 100405.	1.7	6
11	Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours. Investigational New Drugs, 2020, 38, 468-477.	2.6	17
12	Improved survival among patients enrolled in oncology phase 1 trials in recent decades. Cancer Chemotherapy and Pharmacology, 2020, 85, 449-459.	2.3	1
13	73P Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î² and PD-L1, in patients with pretreated biliary tract cancer. Annals of Oncology, 2020, 31, S268-S269.	1.2	6
14	Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î² and PD-L1, in patients with pretreated biliary tract cancer. , 2020, 8, e000564.		98
15	Novel endoscopic technique for trisegment drainage in patients with unresectable hilar malignant biliary strictures (with video). Gastrointestinal Endoscopy, 2020, 92, 763-769.	1.0	7
16	Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer. Investigational New Drugs, 2020, 38, 1836-1845.	2.6	4
17	Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease. Hepatology Communications, 2020, 4, 284-297.	4.3	53
18	Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFÎ² and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. Clinical Cancer Research, 2020, 26, 3202-3210.	7.0	24

#	Article	IF	Citations
19	Firstâ€inâ€human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Science, 2020, 111, 571-579.	3.9	16
20	Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 3063-3063.	1.6	8
21	First-in-human study of the cancer peptide vaccine, TAS0313, in patients with advanced solid tumors: Phase I dose-finding part results.. Journal of Clinical Oncology, 2020, 38, 73-73.	1.6	0
22	An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 3054-3054.	1.6	1
23	Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991â€“2015. Investigational New Drugs, 2019, 37, 166-174.	2.6	4
24	Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. Investigational New Drugs, 2019, 37, 109-117.	2.6	20
25	Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study. Internal Medicine, 2019, 58, 2435-2441.	0.7	4
26	Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. The Lancet Gastroenterology and Hepatology, 2019, 4, 611-621.	8.1	223
27	A phase 1 study of niraparib in Japanese patients with advanced solid tumors. Annals of Oncology, 2019, 30, vi127.	1.2	0
28	Phase I study of nivolumab or nivolumab/cisplatin/gemcitabine to treat unresectable/recurrent biliary tract cancer. Annals of Oncology, 2019, 30, vi86-vi87.	1.2	0
29	First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics, 2019, 18, 531-540.	4.1	49
30	Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials. Frontiers in Oncology, 2019, 9, 301.	2.8	1
31	Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors. Annals of Oncology, 2019, 30, vi107.	1.2	1
32	Targeted-sequencing in rare cancers and the impact on patient treatment.. Journal of Clinical Oncology, 2019, 37, e14755-e14755.	1.6	3
33	A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.. Journal of Clinical Oncology, 2019, 37, 306-306.	1.6	4
34	Germline mutations in cancer-predisposition genes in patients with biliary tract cancer. Oncotarget, 2019, 10, 5949-5957.	1.8	9
35	AB053. P-21. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor Î² (TGF-Î²) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): efficacy by BTC subtype. Hepatobiliary Surgery and Nutrition, 2019, 8, AB053-AB053.	1.5	2
36	Phase I study of cemiplimab, a human monoclonal antibody to programmed death (PD)-1, in Japanese patients (pts) with advanced malignancies: Results from the dose exploration.. Journal of Clinical Oncology, 2019, 37, 33-33.	1.6	0

#	Article	IF	Citations
37	A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2018, 36, 647-656.	2.6	17
38	Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with <scp>BRAF</scp> V600 mutationâ€positive advanced cutaneous melanoma. Journal of Dermatology, 2018, 45, 397-407.	1.2	22
39	Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. Journal of Gastroenterology, 2018, 53, 1159-1167.	5.1	7
40	Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment. Oncology, 2018, 94, 72-78.	1.9	11
41	Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-Î², in patients with pretreated recurrent or refractory gastric cancer. Annals of Oncology, 2018, 29, viii222-viii223.	1.2	11
42	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-Î², in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial. Annals of Oncology, 2018, 29, viii258-viii259.	1.2	14
43	Evaluating Clinical Genome Sequence Analysis by Watson for Genomics. Frontiers in Medicine, 2018, 5, 305.	2.6	15
44	An open-label phase 1 trial of lenvatinib plus pembrolizumab in patients with advanced selected solid tumors. Annals of Oncology, 2018, 29, vii81.	1.2	1
45	Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and handâ€foot skin reactions in sorafenib-treated patients. Cancer Chemotherapy and Pharmacology, 2018, 82, 677-684.	2.3	20
46	Oral chemotherapy for the treatment of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2018, 19, 993-1001.	1.8	13
47	Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma. Oncotarget, 2018, 9, 16883-16890.	1.8	25
48	An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. Oncologist, 2017, 22, 158-164.	3.7	24
49	Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer. Pancreas, 2017, 46, 335-340.	1.1	75
50	Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors. Oncology, 2017, 92, 353-359.	1.9	11
51	Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 1169-1177.	2.3	37
52	Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan. International Journal of Clinical Oncology, 2017, 22, 780-785.	2.2	0
53	Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors. Japanese Journal of Clinical Oncology, 2017, 47, 826-831.	1.3	10
54	Quality evaluation of investigatorâ€initiated trials using postâ€approval cancer drugs in Japan. Cancer Science, 2017, 108, 995-999.	3.9	2

#	Article	IF	Citations
55	Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer. Investigational New Drugs, 2017, 35, 37-46.	2.6	26
56	Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. Japanese Journal of Clinical Oncology, 2016, 46, hyv179.	1.3	7
57	Molecular-targeted Therapies in Gastrointestinal Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1051-1060.	0.0	0
58	C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer. Pancreas, 2016, 45, 110-116.	1.1	37
59	Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 281-288.	2.3	51
60	Tremelimumab-associated tumor regression following after initial progression: two case reports. Immunotherapy, 2016, 8, 9-15.	2.0	12
61	Trends in the development of MET inhibitors for hepatocellular carcinoma. Future Oncology, 2016, 12, 1275-1286.	2.4	24
62	Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. Pancreatology, 2016, 16, 99-105.	1.1	25
63	Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World Journal of Gastroenterology, 2016, 22, 7440.	3.3	15
64	Cytotoxic chemotherapy for pancreatic neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 628-633.	2.6	20
65	Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 623-627.	2.6	18
66	Clinical Development of Immune Checkpoint Inhibitors. BioMed Research International, 2015, 2015, 1-12.	1.9	51
67	Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. Hepatology Research, 2015, 45, 1220-1227.	3.4	14
68	Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. Journal of Gastroenterology, 2015, 50, 667-674.	5.1	36
69	Assessment of adverse events via a telephone consultation service for cancer patients receiving ambulatory chemotherapy. BMC Research Notes, 2015, 8, 315.	1.4	16
70	Human papillomavirus infection and immunohistochemical expression of cell cycle proteins pRb, p53, and p16INK4a in sinonasal diseases. Infectious Agents and Cancer, 2015, 10, 23.	2.6	35
71	A retrospective analysis of factors associated with selection of end-of-life care and actual place of death for patients with cancer. BMJ Open, 2014, 4, e004352.	1.9	5
72	Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Science, 2014, 105, 354-358.	3.9	9

#	Article	IF	Citations
73	Twenty-six Cases of Advanced Ampullary Adenocarcinoma Treated with Systemic Chemotherapy. Japanese Journal of Clinical Oncology, 2014, 44, 324-330.	1.3	11
74	Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Journal of Gastroenterology, 2014, 49, 932-940.	5.1	36
75	Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. Investigational New Drugs, 2014, 32, 928-936.	2.6	5
76	Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial. BMC Cancer, 2014, 14, 301.	2.6	10
77	Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Investigational New Drugs, 2013, 31, 1265-1274.	2.6	39
78	Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. International Journal of Clinical Oncology, 2013, 18, 207-213.	2.2	75
79	Gemcitabine in Patients With Intraductal Papillary Mucinous Neoplasm With an Associated Invasive Carcinoma of the Pancreas. Pancreas, 2013, 42, 889-892.	1.1	6
80	Glycemia Control Using A1C Level in Terminal Cancer Patients with Preexisting Type 2 Diabetes. Journal of Palliative Medicine, 2013, 16, 790-793.	1.1	9
81	Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. British Journal of Cancer, 2013, 109, 739-746.	6.4	65
82	A Case of Pathological Complete Response after Combination Chemotherapy by Sorafenib and Cisplatin Hepatic Arterial Infusion for an Advanced Hepatocellular Carcinoma. Japanese Journal of Gastroenterological Surgery, 2013, 46, 915-923.	0.1	0
83	Gemcitabine-induced Pleuropericardial Effusion in a Patient with Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 845-850.	1.3	12
84	Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma. Case Reports in Oncology, 2012, 5, 515-519.	0.7	7
85	Successful Control of Intractable Hypoglycemia Using Radiopharmaceutical Therapy with Strontium-89 in a Case with Malignant Insulinoma and Bone Metastases. Japanese Journal of Clinical Oncology, 2012, 42, 640-645.	1.3	4
86	Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer. Clinical Cancer Research, 2012, 18, 6326-6338.	7.0	43
87	Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma. Neuroendocrinology, 2012, 96, 324-332.	2.5	48
88	Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy. BMC Cancer, 2012, 12, 268.	2.6	16
89	Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis. BMC Cancer, 2012, 12, 609.	2.6	11
90	Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. Pancreatology, 2012, 12, 428-433.	1.1	5

#	Article	IF	Citations
91	Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients. Cancer Chemotherapy and Pharmacology, 2012, 69, 957-964.	2.3	8
92	Transcatheter Arterial Infusion Chemotherapy with a Fine-powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Japanese Journal of Clinical Oncology, 2011, 41, 770-775.	1.3	28
93	Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer. Journal of Immunotherapy, 2011, 34, 92-99.	2.4	91
94	Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma. Pancreas, 2011, 40, 415-421.	1.1	35
95	Long-Term Administration of Wilms Tumor-1 Peptide Vaccine in Combination with Gemcitabine Causes Severe Local Skin Inflammation at Injection Sites. Japanese Journal of Clinical Oncology, 2010, 40, 1184-1188.	1.3	6
96	Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases. Oncology, 2010, 79, 39-45.	1.9	23
97	Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas. Japanese Journal of Clinical Oncology, 2010, 40, 313-318.	1.3	149
98	Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients. Clinical Pharmacokinetics, 2010, 49, 549-558.	3.5	43
99	Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?. Oncology, 2009, 77, 217-223.	1.9	28
100	Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. British Journal of Cancer, 2009, 100, 870-873.	6.4	56
101	SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration. Biochemical and Biophysical Research Communications, 2009, 382, 210-214.	2.1	7
102	Spontaneous regression of hepatocellular carcinoma. International Journal of Clinical Oncology, 2006, 11, 407-411.	2.2	42
103	Cytogenetic Confirmation of a Gastrointestinal Stromal Tumor and Ewing Sarcoma/Primitive Neuroectodermal Tumor in a Single Patient. Japanese Journal of Clinical Oncology, 2005, 35, 753-756.	1.3	15
104	Complicated paraneoplastic neurological syndromes: a report of two patients with small cell or non-small cell lung cancer. Clinical Neurology and Neurosurgery, 2003, 106, 47-49.	1.4	22